	porporany.	
It is made available	under a CC-BY	4.0 International license .

1	Effects of low versus high inspired oxygen fraction on
2	myocardial injury after transcatheter aortic valve
3	implantation: A randomized clinical trial
4	
5	Youn Joung Cho <sup>1</sup> , Cheun Hyeon <sup>1</sup> , Karam Nam <sup>1</sup> , Seohee Lee <sup>1</sup> , Jae-Woo Ju <sup>1</sup> , Jeehoon Kang <sup>2</sup> , Jung-
6	Kyu Han <sup>2</sup> , Hyo-Soo Kim <sup>2</sup> , Yunseok Jeon <sup>1*</sup>
7	
8	<sup>1</sup> Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul
9	National University College of Medicine, Seoul, South Korea
10	<sup>2</sup> Department of Internal Medicine, Seoul National University Hospital, Seoul National University
11	College of Medicine, Seoul, South Korea
12	
13	* Corresponding author
14	E-mail: jeonyunseok@gmail.com
15	
16	Short title: oxygen fraction and myocardial injury in transcatheter aortic valve implantation
17	
18	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 19 Abstract

20

## 21 Background

- 22 Oxygen therapy is used in various clinical situation, but its clinical outcomes are inconsistent.
- The relationship between the fraction of inspired oxygen  $(F_1O_2)$  during transcatheter aortic
- valve implantation (TAVI) and clinical outcomes has not been well studied. We investigated
- the association of  $F_1O_2$  (low vs. high) and myocardial injury in patients undergoing TAVI.

#### 26 Methods

27 Adults undergoing transfemoral TAVI under general anesthesia were randomly assigned to

receive  $F_1O_2$  0.3 or 0.8 during procedure. The primary outcome was the area under the curve

29 (AUC) for high-sensitivity cardiac troponin I (hs-cTnI) during the first 72 h following TAVI.

30 Secondary outcomes included the AUC for postprocedural creatine kinase-myocardial band

31 (CK-MB), acute kidney injury and recovery, conduction abnormalities, pacemaker

32 implantation, stroke, myocardial infarction, and in-hospital mortality.

#### 33 **Results**

- Between October 2017 and April 2022, 72 patients were randomized and 62 were included in
- the final analysis (n=31 per group). The median (IQR) AUC for hs-cTnI in the first 72 h was
- $42.66 (24.82-65.44) \text{ and } 71.96 (35.38-116.34) \text{ h} \cdot \text{ng/mL} \text{ in the } F_1O_2 0.3 \text{ and } 0.8 \text{ groups},$
- respectively (p=0.066). The AUC for CK-MB in the first 72 h was 257.6 (155.6–322.0) and
- 38 342.2 (195.4–485.2)  $h \cdot ng/mL$  in the F<sub>I</sub>O<sub>2</sub> 0.3 and 0.8 groups, respectively (p=0.132). Acute
- kidney recovery, defined as an increase in the estimated glomerular filtration rate  $\geq 25\%$  of
- 40 baseline in 48 h, was more common in the  $F_1O_2$  0.3 group (65% vs. 39%, p=0.042). Other
- 41 clinical outcomes were comparable between the groups.

#### 42 **Conclusions**

- 43 The  $F_1O_2$  level did not have a significant effect on periprocedural myocardial injury following
- 44 TAVI. However, considering the marginal results, a benefit of low F<sub>1</sub>O<sub>2</sub> during TAVI could
- 45 not be ruled out.
- 46
- 47 Keywords: transcatheter aortic valve implantation; intraoperative oxygen; fraction of
- 48 inspired oxygen; oxygen therapy; myocardial injury
- 49
- 50

# 51 Introduction

52

Although a fraction of inspired oxygen  $(F_1O_2)$  higher than that of ambient air is generally 53 used during general anesthesia, there is continuing debate about the optimal  $F_1O_2$ . High 54 oxygen tension is beneficial for reducing surgical site infection and in 2016 World Health 55 Organization recommended that adults receive F<sub>I</sub>O<sub>2</sub> 0.8 during mechanical ventilation under 56 general anesthesia [1]. However, a more recent systematic review found no difference in the 57 surgical site infection rate according to the intraoperative F<sub>1</sub>O<sub>2</sub> amount, and suggested a 58 negative effect of high F<sub>I</sub>O<sub>2</sub> on long-term outcomes [2]. Other investigators did not find any 59 difference in the degree of myocardial injury between perioperative F<sub>1</sub>O<sub>2</sub> 0.3 and 0.8, and 60 suggested that  $F_1O_2 0.8$  is safe for major non-cardiac surgery [3]. 61

High oxygen tension may cause oxidative stress, coronary vasoconstriction, and 62 altered microvascular perfusion, resulting in adverse systemic effects including myocardial 63 injury [4]. In a meta-analysis of acute myocardial infarction (MI), there was no evidence to 64 support the routine use of oxygen treatment and the authors could not rule out a harmful 65 effect of unnecessary oxygen therapy [5]. Constant and brief intermittent hyperoxia both 66 induced inflammatory responses and cytotoxicity in cardiomyocytes from adult humans [6]. 67 68 Myocardial injury is common following transcatheter aortic valve implantation (TAVI) [7]. Moreover, abnormally increased cardiac biomarkers were associated with poor outcomes 69 including periprocedural kidney injury and 30-day and 1-year mortality following TAVI [8]. 70 The relationship between the  $F_1O_2$  level and myocardial injury has not been well 71 studied in patients undergoing TAVI. Therefore, this study investigated whether high (0.8) 72 and low (0.3) F<sub>1</sub>O<sub>2</sub> during transfemoral TAVI under general anesthesia have different effects 73 74 on post-procedural myocardial injury, as indexed by serum cardiac troponin in the early post-TAVI period. 75

## 76 Methods

77

## 78 Ethics approval

This randomized controlled trial was approved by the Institutional Review Board of Seoul
National University Hospital (#1707-109-871, on September 11, 2017) and registered at
clinicaltrials.gov (NCT03291210, on September 25, 2017) before patient enrollment. The
study was conducted according to the Good Clinical Practice guidelines and Declaration of
Helsinki. Written informed consent was obtained from all participants, who could withdraw
at any time.

85

## 86 Study population and randomization

Adults (aged 20–99 years) with aortic stenosis (AS), undergoing elective TAVI under general 87 88 anesthesia via the transfemoral approach in a single tertiary academic center (Seoul National University Hospital, South Korea), were eligible for the study. Eligibility for TAVI was 89 based on the consensus of a local multidisciplinary heart team, including clinical 90 cardiologists, cardiac interventionists, cardiac surgeons, radiologists, and anesthesiologists. 91 The predicted operative mortality risk was calculated using the Society of Thoracic Surgeons 92 Predicted Risk of Mortality (STS-PROM) score, European System for Cardiac Operative 93 Risk Evaluation (EuroSCORE) II, and logistic EuroSCORE. The heart team determined the 94 anesthetic method (general anesthesia or conscious sedation) based on the patients' 95 comorbidities, preference, and ability to maintain a supine position without profound dyspnea 96 or restlessness during the procedure. The exclusion criteria were a non-transfemoral 97 approach, pre-procedural arterial partial pressure of oxygen (PaO<sub>2</sub>) <65 mmHg or receiving 98 oxygen treatment, severe pre-procedural renal dysfunction (defined as an estimated 99

glomerular filtration rate [eGFR] <30 mL/min/1.73 m<sup>2</sup>), chronic pulmonary obstructive 100 disease or symptomatic asthma, tuberculosis-destroyed lung, history of lung cancer, acute 101 coronary syndrome within the past 6 months, documented pre-procedural cardiac troponin I 102 (cTnI) or creatine kinase-myocardial band (CK-MB) elevation, stroke or transient ischemic 103 attack within 6 months, pregnancy, and refusal to participate. 104 After enrollment and the informed consent process, the patients were randomized to 105 receive F<sub>1</sub>O<sub>2</sub> 0.3 or 0.8 during TAVI (1:1 allocation ratio) (Fig 1). Block randomization 106 (blocks of four or six) was conducted using a computer-generated program by an independent 107 108 research nurse on the morning of the intervention. The group assignments were concealed in

an opaque envelop, and all investigators, patients, interventionists, and data analyzers wereblinded to the group allocations.

111

Fig 1. CONSORT diagram. CK-MB, creatine kinase-myocardial band; COPD, chronic
 obstructive pulmonary disease; F<sub>1</sub>O<sub>2</sub>, fraction of inspired oxygen; PaO<sub>2</sub>, arterial partial
 pressure of oxygen.

115

#### **Study protocol**

The routine monitoring techniques of our institution for patients under general anesthesia 117 were applied, except  $F_1O_2$  management. Without premedication, 12-lead electrocardiogram, 118 pulse oxygen saturation (SpO<sub>2</sub>), invasive and noninvasive arterial blood pressure, cerebral 119 oxygen saturation (ScrbO<sub>2</sub>), and bispectral index monitoring were performed. Left and right 120 ScrbO<sub>2</sub> were measured using near-infrared spectroscopy (Somanetics INVOS oximeter; 121 Covidien, Mansfield, MA, USA). Transesophageal or transthoracic echocardiography was 122 performed to evaluate the valve position and presence of paravalvular regurgitation, as 123 required by the interventionists. 124

125	Before inducing anesthesia, all participants were preoxygenated using an anesthesia
126	machine (Primus; Drägerwerk, Lubeck, Germany) with F1O2 0.3 or 0.8 according to the
127	group allocation. After stabilization, general anesthesia was induced by a target-controlled
128	infusion of propofol (effect-site concentration [Ce], 2.5–4.0 $\mu$ g/mL) and remifentanil (Ce,
129	1.0-4.0 ng/mL) using a commercial infusion pump (Orchestra, Fresenius Vial, Brézins,
130	France). Neuromuscular blockade was established by administering rocuronium (0.6 mg/kg).
131	Then the trachea was intubated and the lungs were ventilated in volume-controlled mode with
132	a tidal volume of 0.6–0.8 mL/kg and ventilatory rate of 9–12 /min. The alveolar recruitment
133	maneuver was performed at 25 $\text{cmH}_2\text{O}$ for 10 s after tracheal intubation, and a positive end-
134	expiratory pressure of 5 cmH <sub>2</sub> O was applied in all patients. According to the group
135	assignment, $F_IO_2$ was maintained at 0.3 or 0.8 until the end of the TAVI procedure, unless the
136	SpO <sub>2</sub> was $<93\%$ . If desaturation occurred, F <sub>1</sub> O <sub>2</sub> was increased by 0.05–0.1, and an additional
137	alveolar recruitment maneuver was performed as needed to maintain SpO <sub>2</sub> $\ge$ 93% by the
138	attending anesthesiologists. On completing the procedure, 100% $O_2$ was provided to all
139	patients during anesthesia emergence. Patients were extubated in the intervention room,
140	monitored in the cardiovascular care unit for 1–2 days, and then transferred to a general ward.
141	Patients were discharged 5–7 days post-TAVI if they had no procedure-related complications.
142	The TAVI was conducted in accordance with the standard procedures in our
143	institution. Using a transfemoral approach, a balloon-expandable Sapien III valve (Edwards
144	Lifesciences, Irvine, CA, USA), self-expandable Evolut Pro or R valve (Medtronic,
145	Minneapolis, MN, USA), or Lotus valve (Boston Scientific, Natick, MA, USA) was
146	implanted at the diseased aortic valve. The valve was chosen by the heart team based on the
147	size and structure of the native valve and sinus, heights of the coronary artery openings, and
148	considerations regarding future coronary access, the risk of conduction disturbances, and
149	annular calcification. The iliofemoral arteries were accessed under fluoroscopic guidance and

closed percutaneously using Perclose ProGlide vascular suture-mediated closure devices
(Abbott Vascular Devices, Redwood City, CA, USA). Before the procedure, the patients
were given loading doses of dual antiplatelet agents: acetylsalicylic acid and clopidogrel
(both 300 mg). During the procedure, the patients were heparinized with unfractionated
heparin to achieve an activated clotting time >250 s. At completion of the valve implantation,
the effects of heparin were reversed by protamine infusion.

During the procedure, arterial blood gas analysis (ABGA) was performed at four time points: baseline (before anesthesia induction, T1), after inducing general anesthesia (T2), after valve implantation (T3), and at the end of the procedure (T4). ABGA was performed using a GEM® Premier 3000 device (Model 5700; Instrumentation Laboratory, Lexington, MA, USA).

Two serum cardiac biomarkers of myocardial injury, high-sensitivity cTnI (hs-cTnI) 161 and CK-MB, were measured at baseline (before the procedure) and 1, 4, 8, 24, 48, and 72 h 162 after TAVI. hs-cTnI was measured using an Abbott Architect Plus Analyzer (i2000SR; Flex, 163 San Jose, CA, USA), which has a limit of detection of 0.0011 µg/L and limit of blank of 164 0.0007–0.0013  $\mu$ g/L. An hs-cTnI concentration  $\geq$ 99<sup>th</sup> percentile in the normal population 165 (0.028 µg/L) was deemed abnormal. Serum creatinine concentrations were calibrated using 166 isotope dilution mass spectrometry (IDMS). The eGFR was calculated using the modified 167 diet in renal disease (MDRD) equation [9]. 168

169

```
170 IDMS MDRD eGFR = 175 \times (\text{serum creatinine})^{-1.154} \times \text{age}^{-0.203} \times (0.742 \text{ for women})
```

171

Postprocedural acute kidney injury (AKI) was determined based on the serum
creatinine level and urine output according to the Kidney Disease: Improving Global
Outcomes Clinical Practice Guidelines criteria for AKI [10]. AKI was defined as an increase

in serum creatinine  $\geq 1.5$  times the baseline level or by  $\geq 0.3$  mg/dL ( $\geq 26.5$  µmol/L) 175 [AKI<sub>creatinine</sub>], or a urine output <0.5 mL/kg/h for  $\ge 6$  h within 7 days [AKI<sub>urine output</sub>]. AKI 176 occurring >7 days after the procedure was excluded because it might have been unrelated to 177 the procedure. Acute kidney recovery (AKR) was defined as an increase in eGFR of >25% 178 relative to baseline at 48 h post-TAVI [11]. 179 The postprocedural development of new conduction abnormalities and incidence of 180 permanent pacemaker insertion was assessed. Stroke was defined as an acute episode of a 181 focal or global neurological deficit as a result of hemorrhage or infarction, based on the Valve 182 183 Academic Research Consortium-2 (VARC-2) definition [12]. Periprocedural MI was defined based on a combination of new ischemic symptoms or signs and elevated cardiac biomarkers 184 within 72 h following TAVI, according to the VARC-2 definition [12]. 185

186

## 187 Study endpoints and sample size calculation

The primary study outcome was periprocedural myocardial injury, as reflected by the geometric area under the curve (AUC) for periprocedural serum hs-cTnI in the first 72 h post-TAVI, calculated according to the trapezoidal rule. Secondary outcomes were the AUC for serum CK-MB in the first 72 h post-TAVI, and the peak serum hs-cTnI and CK-MB levels in the same period. Post-procedural clinical outcomes were also evaluated, including AKI, AKR, new conduction abnormalities, permanent pacemaker insertion, stroke, MI, and inhospital cardiovascular mortality.

To calculate the sample size, we conducted a pilot study of 10 patients undergoing transfemoral TAVI under general anesthesia. The AUC for serum hs-cTnI in the first 72 h after TAVI was  $40.24 \pm 28.16$  ng/mL. Assuming that a 50% difference in hs-cTnI levels between the two treatment groups in the first 72 h is clinically relevant, 32 patients were required for each group at 80% power and an alpha error of 5%. Considering a 10% dropout

rate, we recruited 36 patients to each group (a total of 72 patients).

201

#### 202 Statistical analysis

Data are presented as the mean  $\pm$  SD, median (interquartile range, IQR), or number (%) after 203 normality was tested using the Kolmogorov-Smirnov test. The primary endpoint, i.e., the 204 AUC for serum hs-cTnI in the first 72 h after TAVI, was analyzed using the Mann–Whitney 205 U test according to the data distribution. Other continuous variables were analyzed using the 206 independent *t*-test or Mann–Whitney *U* test after performing a normality test. Categorical 207 208 variables were analyzed using Pearson's chi square test or Fisher's exact test. For repeated measures, a linear mixed model with Bonferroni correction was used to compare the groups. 209 In the mixed model, group, measurement time, and their interaction were fixed effects, while 210 subject was a random effect. Plots of residuals versus fitted values were checked in terms of 211 whether the error terms (residuals) had a mean of zero and constant variance. The normality 212 assumption for repeated measures was assessed using histograms and quantile-quantile plots 213 (for residuals). Multivariable logistic regression analysis was performed to identify 214 independent risks for F<sub>1</sub>O<sub>2</sub> and postprocedural hs-cTnI. Odds ratios (ORs) were adjusted for 215 age, sex, STS-PROM score, C-reactive protein, left ventricular (LV) ejection fraction (EF), 216 procedural time, and new conduction abnormality, and 95% confidence intervals (CIs) were 217 presented. The analysis was done in an intention-to-treat manner. All analyses were 218 219 performed using IBM SPSS Statistics (ver. 21.0; IBM Corp., Armonk, NY, USA) or R software (ver. 3.5.1; R Development Core Team, Vienna, Austria). A P value <0.05 was 220 considered statistically significant. 221 222

# 223 **Results**

224

225	Patients were screened for eligibility between October 18, 2017 and April 6, 2022. Of 189
226	patients, 117 were excluded based on the exclusion criteria (Fig 1). After 72 patients were
227	randomized to the $F_1O_2$ 0.3 or 0.8 groups (n=36 each), 10 patients were excluded due to pre-
228	procedural $PaO_2 < 65 \text{ mmHg}$ (n=4), elevated pre-procedural cTnI (n=5), or procedure
229	cancellation (n=1). We noted violations of the exclusion criteria (pre-procedural $PaO_2 < 65$
230	mmHg or elevated cardiac biomarkers) in nine patients and excluded them from the analysis.
231	Thus, a total of 62 patients (31 per group) were included in the final analysis. We performed
232	additional sub-analysis including five patients (n=2 in the $F_1O_2$ 0.3 group and n=3 in the $F_1O_2$
233	0.8 group) who had elevated cardiac biomarkers after randomization.
234	Tables 1 and 2 present the baseline characteristics of the included patients and
235	procedural variables. Baseline characteristics were well balanced between the groups. The
236	median (IQR) age of the included patients was 79 (77-83) years. The median (IQR)
237	procedural duration was 80 (70–95) min.
238	

#### 239 Table 1. Baseline characteristics in patients undergoing transfemoral transcatheter

240 aortic valve implantation.

	$F_IO_2 0.3$	$F_IO_2 0.8$	p value
	(n=31)	(n=31)	
Demographics			
Age, yr	79 (76–82 [range 64–90])	79 (77–84 [range 58–94])	0.783
Male	12 (39%)	12 (39%)	>0.999
Height, cm	$156\pm10.0$	157 ± 10	0.776
Weight, kg	59.1 ± 10.7	60.0 ± 11.0	0.742

It is made available under a CC-BY 4.0 International license .	It is made available under a	CC-B	Y 4.0 International license
--	------------------------------	------	-----------------------------

Body mass index, kg/m <sup>2</sup>	$24.29\pm3.72$	24.42 ± 3.69	0.892
Body surface area, m <sup>2</sup>	$1.58\pm0.17$	$1.59 \pm 0.18$	0.740
Current smoker	1 (3%)	0 (0%)	0.313
NYHA functional class			0.496
Ι	8 (26%)	6 (19%)	
II	14 (45%)	18 (58%)	
III/IV	9 (29%)	7 (23%)	
Predicted risk calculation			
STS PROM, %	2.759 (1.936–3.724)	3.162 (2.370-4.060)	0.269
EuroSCORE II, %	2.72 (1.64-3.95)	3.54 (1.35-7.01)	0.356
Logistic EuroSCORE, %	4.52 (1.56–7.46)	4.83 (1.95-7.01)	0.564
Echocardiographic and CT data			
LV EF, %	63 (59–67)	66 (61–68)	0.441
AV area, cm <sup>2</sup>	0.7 (0.6–0.8)	0.7 (0.6–0.9)	0.309
AV peak velocity, m/s	$4.6 \pm 0.4$	$4.6 \pm 0.6$	0.736
AV mean pressure gradient,	49 (44–60)	50 (43–66)	0.933
mmHg			
AV perimeter, mm	73.0 ± 6.4	72.0 ± 5.6	0.513
LVIDd, mm	46 (42–50)	46 (41–49)	0.534
LVIDs, mm	28 (25-32)	27 (24–31)	0.398
Stroke volume, mL	77 ± 22	81 ± 17	0.538
Height of LMCA os from annulus,	12.7 ± 2.4	12.2 ± 2.2	0.409
mm			
Height of RCA os from annulus,	14.7 ± 2.3	$14.2 \pm 2.5$	0.410
mm			
Baseline laboratory findings			
Hematocrit, %	36.0 ± 4.3	34.8 ± 4.6	0.776
eGFR, ml/min/1.73 m <sup>2</sup>	67.5 ± 16.9	66.5 ± 16.0	0.809
Creatinine, mg/dL	0.88 (0.81–1.05)	0.91 (0.76–1.13)	0.800

Albumin, g/dL	4.0 (3.9–4.3)	4.0 (3.7–4.3)	0.666
hs-cTnI, ng/mL	0.00 (0.00-0.00)	0.00 (0.00-0.00)	0.757
CK-MB, ng/mL	1.1 (1.1–1.4)	1.0 (0.8–1.2)	0.065
hs-CRP, mg/dL	0.07 (0.04–0.33)	0.07 (0.04–0.14)	0.750
Comorbidities			
Hypertension	26 (84%)	22 (71%)	0.224
Diabetes	7 (23%)	11 (36%)	0.263
Dyslipidemia	17 (55%)	21 (68%)	0.297
Coronary artery disease	6 (19%)	7 (23%)	0.755
Angina/previous MI	7 (23%)	6 (19%)	0.755
Medications			
Aspirin	13 (42%)	13 (42%)	>0.999
Anti-platelet agents	12 (39%)	16 (52%)	0.307
Non-vitamin K anticoagulants	3 (10%)	3 (10%)	>0.999
Beta-blockers	19 (61%)	16 (52%)	0.442
ARB/ACEi	20 (65%)	18 (58%)	0.602
Calcium channel blockers	11 (36%)	15 (48%)	0.303
Oral hypoglycemic agents	8 (26%)	9 (29%)	0.776
Diuretics	17 (55%)	14 (45%)	0.446
Nitrates	6 (19%)	4 (13%)	0.490
Statin	19 (61%)	22 (71%)	0.421

Values are median (interquartile range), n (%), or mean  $\pm$  SD.

242 ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; AV,

aortic valve; CK-MB, creatine kinase-myocardial band; COPD, chronic obstructive

- pulmonary disease; CT, computed tomography; EF, ejection fraction; eGFR, estimated
- 245 glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk

Evaluation; F<sub>1</sub>O<sub>2</sub>, fraction of inspired oxygen; hs-CRP, high-sensitivity C-reactive protein;

247 hs-cTnI, high-sensitivity cardiac troponin I; LMCA, left main coronary artery; LV, left

- ventricular; LVIDd, left ventricular internal diameter end diastole; LVIDs, left ventricular
- 249 internal diameter end systole; MI, myocardial infarction; NYHA, New York Heart
- 250 Association; RCA, right coronary artery; STS PROM, Society of Thoracic Surgeons
- 251 Predicted Risk of Mortality; TIA, transient ischemic attack.
- 252

#### 253 Table 2. Valve characteristics and procedural variables in patients undergoing

transfemoral transcatheter aortic valve implantation.

	$F_IO_2 0.3$	$F_IO_2 0.8$	p value
	(n=31)	(n=31)	
Prosthetic valve type			0.647
Sapien III	13 (42%)	14 (45%)	
Evolut Pro or R	15 (48%)	12 (39%)	
Lotus valve	3 (10%)	5 (16%)	
Prosthetic valve size, mm			0.698
23	6 (19%)	9 (29%)	
25	1 (3%)	2 (7%)	
26	18 (58%)	14 (45%)	
29	6 (19%)	6 (19%)	
Paravalvular regurgitation			0.112
No	12 (39%)	13 (42%)	
Trivial	9 (29%)	15 (48%)	
Mild	9 (29%)	2 (7%)	
Moderate	1 (3%)	1 (3%)	
Procedure duration, min	80 (70–95)	80 (70–95)	0.860
Anesthesia duration, min	140 (120–155)	135 (120–160)	0.888
Amount of contrast media, mL	250 (200–288)	250 (210–326)	0.404

Transfusion of pRBC, unit	0 (0–1)	0 (0–1)	0.675
---------------------------	---------	---------	-------

255 Values are n (%) or median (interquartile range).

- $F_{IO_2}$ , fraction of inspired oxygen; pRBC, packed red blood cell.
- 257

During the procedure, PaO<sub>2</sub>, arterial oxygen saturation (SaO<sub>2</sub>), and SpO<sub>2</sub> were higher 258 in the  $F_1O_2$  0.8 than  $F_1O_2$  0.3 group (Fig 2). Two patients in the  $F_1O_2$  0.3 group required 259 adjustment of  $F_1O_2$  to 0.4 during the procedure because transient SpO<sub>2</sub> <93% was observed. 260 The mean left and right cerebral oximetry values were higher in the  $F_1O_2$  0.8 than  $F_1O_2$  0.3 261 group (Fig 2). For serial measurements, interactions between measurement time and group 262 were significant for PaO<sub>2</sub>, SaO<sub>2</sub>, and the mean ScrbO<sub>2</sub> (p<0.001, <0.001, and 0.032, 263 respectively), but not for  $SpO_2$  (p=0.330). 264 265 Fig 2. Changes in arterial oxygenation, pulse oxygen saturation, and cerebral oximetry 266 in patients receiving a fraction of inspired oxygen of 0.3 or 0.8 during transcatheter 267 aortic valve implantation. F<sub>1</sub>O<sub>2</sub>, fraction of inspired oxygen; PaO<sub>2</sub>, arterial partial pressure 268 of oxygen; SaO<sub>2</sub>, arterial oxygen saturation; SpO<sub>2</sub>, pulse oxygen saturation; ScrbO<sub>2</sub>, cerebral 269 oxygen saturation. \* p < 0.001 compared to the F<sub>1</sub>O<sub>2</sub> 0.3 group. # p = 0.003 between the 270 groups (mixed model). § p < 0.05 compared to the F<sub>1</sub>O<sub>2</sub> 0.3 group. 271 272

The primary outcome, the AUC for serum hs-cTnI in the first 72 h post-TAVI, was higher in the  $F_1O_2$  0.8 than  $F_1O_2$  0.3 group (71.96 [35.38–116.34] vs. 42.66 [24.82–65.44] h·ng/mL), but the difference was not statistically significant (p=0.066) (Fig 3). The secondary outcome (AUC for CK-MB in the first 72 h post-TAVI) was also higher in the  $F_1O_2$  0.8 group, but not significantly (342.2 [195.4–485.2] vs. 257.6 [155.6–322.0] h·ng/mL; p=0.132) (Fig 3). The peak hs-cTnI and CK-MB levels during the first 72 h post-TAVI were also non-

significantly higher in the F<sub>I</sub>O<sub>2</sub> 0.8 group (1.79 [1.09–3.77] vs. 1.30 [1.00–1.58] ng/mL and 279 10.9[5.7-15.6] vs. 7.5[6.0-11.9] ng/mL: p=0.051 and 0.159, respectively). For 280 periprocedural serial measurements, the group differences in hs-cTnI and CK-MB did not 281 reach statistical significance (p=0.125 and 0.084, respectively; mixed model). The interaction 282 between measurement time and group was not significant (p=0.200 and 0.096 for hs-cTnI and 283 CK-MB, respectively). When including the five patients who completed the study protocol 284 285 and were excluded from the final analysis due to elevated baseline hs-cTnI after randomization, there were no significant differences in the AUCs for hs-cTnI and CK-MB in 286 287 the first 72 h post-TAVI between the groups (S1 Fig). After adjustment for various risk factors, there was no significant association between the F1O2 and AUC for hs-cTnI post-288 TAVI (OR: 3.644, 95% CI: 0.864–15.371; p=0.078). 289 290 Fig 3. Changes in cardiac biomarkers in the first 72 h in patients who received a 291 fraction of inspired oxygen of 0.3 or 0.8 during transcatheter aortic valve implantation. 292 AUC, area under the curve; CK-MB, creatine kinase-myocardial band; hs-cTnI, high-293 sensitivity cardiac troponin I; TAVI, transcatheter aortic valve implantation. 294 295 The postprocedural incidence of AKI did not differ between F<sub>I</sub>O<sub>2</sub> 0.3 and 0.8 groups 296 (36% vs. 42%; p=0.602) (Table 3). However, AKR was more frequent in the F<sub>1</sub>O<sub>2</sub> 0.3 than 297  $F_1O_2$  0.8 group (65% vs. 39%; p=0.042). Other postprocedural clinical outcomes, such as 298 cardiovascular mortality or length of hospitalization, were comparable between the two 299 groups (Table 3). 300 301

Table 3. Postprocedural variables in patients received fraction of inspired oxygen 0.3 or
0.8 during transfemoral transcatheter aortic valve implantation.

	F <sub>I</sub> O <sub>2</sub> 0.3	F <sub>1</sub> O <sub>2</sub> 0.8	p value
	(n=31)	(n=31)	
Echocardiographic data (at discharge)			
LV EF, %	63 (60–67)	65 (62–69)	0.140
AV area, cm <sup>2</sup>	1.8 (1.5–2.1)	1.6 (1.3–1.9)	0.126
AV peak velocity, m/s	$2.2 \pm 0.4$	$2.3 \pm 0.5$	0.350
AV mean pressure gradient, mmHg	10 (6–13)	11 (8–14)	0.386
LVIDd, mm	45 (42–48)	45 (43-47)	0.854
LVIDs, mm	27 (25–31)	27 (25–30)	0.685
Stroke volume, mL	74 ± 24	71 ± 17	0.538
Peak creatinine within 7 days, mg/dL	0.87 (0.77–0.99)	0.89 (0.74–1.16)	0.508
Peak hs-CRP within 72 h, mg/dL	3.71 ± 2.21	4.38 ± 3.23	0.393
	4.14 (1.56–5.22)	4.25 (2.01–5.84)	0.694
AKI within 7 days	11 (36%)	13 (42%)	0.602
AKI <sub>creatinine</sub>	0 (0%)	3 (10%)	0.238
AKI <sub>urine output</sub>	11 (36%)	12 (39%)	0.793
AKR within 48 h	20 (65%)	12 (39%)	0.042
Both AKI and AKR	7 (23%)	3 (10%)	0.167
New conduction abnormality	15 (48%)	11 (36%)	0.303
PPM insertion	3 (10%)	4 (13%)	> 0.999
Stroke	1 (3%)	1 (3%)	> 0.999
Myocardial infarction	0	0	
In-hospital mortality	0	0	
Post-procedural hospital length of stay, days	6 (5–7)	5 (5-7)	0.403

Values are median (interquartile range), mean  $\pm$  SD, or n (%). AKI was defined as an 304

increase in serum creatinine  $\geq$  1.5 times the baseline level or by  $\geq$  0.3 mg/dL ( $\geq$  26.5 µmol/L) 305

for [AKI<sub>creatinine</sub>], or urine output < 0.5 mL/kg/h for  $\ge 6 \text{ h}$  within 7 days for [AKI<sub>urine output</sub>]. 306

AKI, acute kidney injury; AKR, acute kidney recovery; AV, aortic valve; EF, ejection 307

fraction; F<sub>I</sub>O<sub>2</sub>, fraction of inspired oxygen; LV, left ventricular; LVIDd, left ventricular 308

- internal diameter end diastole; LVIDs, left ventricular internal diameter end systole; PPM,
- 310 permanent pacemaker.

# 312 **Discussion**

313

Compared to the  $F_1O_2$  0.3 group, the  $F_1O_2$  0.8 group showed a greater postprocedural elevation of cardiac biomarkers, albeit without statistical significance. Postprocedural AKR was more frequent in the  $F_1O_2$  0.3 group. There was no difference in other periprocedural outcomes between the groups.

318

### 319 Myocardial injury after TAVI

320 Even after successful TAVI, the cardiac biomarkers cTnI and CK-MB showed post-

321 procedure increases despite prompt relief of transvalvular pressure overload, and

322 periprocedural myocardial injury occurred along with transient deterioration in myocardial

function [13]. Significant deterioration in the myocardial performance index, which implies

both systolic and diastolic dysfunction, was observed immediately following TAVI [13].

New myocardial late enhancement with an ischemic pattern, indicating myocardial damage,

326 was detected on cardiac magnetic resonance images following both balloon-expandable and

327 self-expandable valve implantation [14].

Transient LV dysfunction and injury following TAVI seems to be partly influenced 328 by procedural aspects of transcatheter valve deployment [15]. Procedure-related mechanical 329 trauma during TAVI, including during balloon valvuloplasty, valve positioning, and 330 prosthesis delivery, also plays a substantial role in myocardial damage [16]. Rapid ventricular 331 pacing is used to temporarily reduce the LV output during pre-implantation balloon 332 valvuloplasty and balloon-expandable valve implantation, and for post-implantation 333 ballooning to reduce paravalvular leakage. Rapid ventricular pacing transiently reduces 334 microvascular tissue perfusion and the flow index in small- and medium-sized vessels, and 335

induces partial microcirculatory arrest and delayed recovery of microflow [17]. Subsequently,
ventricular stunning and subsequent dysfunction may occur [15].

338

## 339 Hyperoxia and myocardial injury

The role of oxidative stress in reperfusion injury is relatively well established. Abrupt 340 oxidative reactions following reperfusion produce reactive oxygen species (ROS) from 341 cardiomyocytes and endothelial cells, which amplifies local inflammatory responses and 342 leads to a vicious cycle of ROS production [18]. The biological mechanism underlying the 343 adverse effects of hyperoxia is related to the generation of ROS, specifically the superoxide 344 anion, which has a negative impact on coronary blood flow and LV distensibility [19]. 345 Hyperoxia can exacerbate oxidative stress and thereby worsen coronary vasoconstriction and 346 myocardial injury. Interestingly, hyperoxic reperfusion limited myocardial necrosis in rodents 347 348 with cardiovascular risk factors more so than in a normoxemic reperfusion group, while the reverse occurred in healthy rodents [18]. Similarly, in a preliminary canine MI model, 349 administering 100% oxygen had beneficial effects on the myocardium by reducing 350 myocardial infarct size and improving the EF after reperfusion compared to room-air 351 ventilation [20]. 352

However, in the AVOID trial, patients presenting with acute MI were randomized to 353 receive oxygen 8 L/min via face mask or ambient air, and oxygen treatment increased 354 myocardial injury and infarct size in patients without hypoxia [21]. In patients admitted to the 355 intensive care unit (ICU), conservative use of oxygen, which aimed to maintain arterial 356 oxygen tension within the physiological range, reduced ICU mortality compared to 357 conventional use of oxygen [22]. In the large randomized DETO2X-AMI study, there was no 358 359 difference in 1-year mortality or the peak cardiac troponin level between patients with suspected MI who received supplemental oxygen versus ambient air [23]. During general 360

361	anesthesia for major non-cardiac surgery, there was no difference in myocardial injury-
362	assessed using the AUC for high-sensitive troponin in the first 3 postoperative days—
363	between $F_1O_2 0.3$ and 0.8 administered intraoperatively and for 2 h after surgery [3]. In the
364	ICU-ROX study, conservative use of $F_1O_2$ ( $\leq 0.21$ ) during mechanical ventilation in adult ICU
365	patients resulted in no difference in the number of ventilator-free days compared to standard
366	administration of F <sub>1</sub> O <sub>2</sub> [24]. In a more recent nationwide registry trial, high oxygen
367	supplementation (6–8 L/min by face mask) resulted in no significant difference in the 30-day
368	or 1-year mortality rate in patients with suspected acute coronary syndrome compared to low
369	oxygen treatment [25].

370

# 371 Myocardial injury and clinical outcomes after TAVI

Cardiac biomarkers elevation following surgery or intervention result from perioperative 372 hemodynamic stress, inflammation, or oxygen supply and demand imbalance [26]. 373 Periprocedural myocardial injury following TAVI was associated with a significantly 374 increased risk of poor short- and long-term clinical outcomes, including 30-day and 1-year 375 mortality, neurological events, and postprocedural permanent pacemaker implantation [27]. 376 In our study, high oxygen tension during TAVI tended to increase the release of 377 cardiac biomarkers in the first 72 h post-TAVI compared to the low oxygen tension group, 378 but the difference was not significant. There was no clinical impact of the level of 379 intraoperative oxygen tension during TAVI, except that recovery of kidney function was 380 more common in the low- compared to the high- $F_1O_2$  group. 381

382

#### **383** Acute kidney recovery

Acute kidney recovery, which is a relatively recently described phenomenon, has been
observed more frequently than AKI after both TAVI and surgical aortic valve replacement

(SAVR) [28]. Following TAVI or SAVR, normalization of the aortic valve area, prompt 386 relief of the trans-aortic pressure gradient, and normalization of post-stenotic flow 387 abnormality occur. Regarding renal blood flow, a rapid increase in cardiac output and 388 reduced LV afterload may cause abrupt hemodynamic changes in the early postprocedural 389 period, such as renal congestion. In a recent prospective registry analysis, both AKI and AKR 390 early after TAVI were independent predictors of cardiovascular mortality [29]. In our study 391 392 cohort, 10 of the 62 (16%) patients met the criteria for both AKI and AKR during the study period (Table 3). Rapid changes in renal hemodynamics could have occurred in these groups, 393 394 and both post-TAVI AKI and AKR may reflect a cardiorenal aspect of the extra-cardiac damage characterizing severe AS. Further studies are required to assess the relationship 395 between renal circulatory changes and clinical outcomes in AS patients following TAVI. 396

397

#### 398 Study limitations

This study has some limitations. First, it was a single-center trial with relatively few patients, 399 and was only powered for one surrogate cardiac biomarker, hs-cTnI. Although we observed a 400 401 trend toward reduced hs-cTnI release and better postprocedural kidney recovery, we cannot definitely conclude that arterial oxygenation is beneficial for patients undergoing TAVI in 402 terms of periprocedural myocardial and renal protection. Second, we included patients 403 undergoing general anesthesia for transfemoral TAVI in this study. However, many patients 404 undergo TAVI under conscious sedation or even local anesthesia, unless they are at very high 405 periprocedural risk due to severely compromised cardiopulmonary function or the inability to 406 maintain a stable supine position, for example. Nevertheless, the included patients had 407 comparable characteristics regarding potential risk factors for postprocedural myocardial 408 409 injury between the two groups. Future investigators could compare the oxygenation strategies of minimal supplemental oxygen and no supplemental oxygen, as in the treatment of acute 410

MI patients without hypoxia, in terms of the likelihood of avoiding unnecessary 411 periprocedural oxidative stress and protecting multiple organ systems, in patients undergoing 412 TAVI under conscious sedation or local anesthesia. Third, we included relatively low-risk 413 patients; we excluded those who were already hypoxemic or required supplemental oxygen, 414 and those with acute coronary syndrome or renal failure. In high-risk patients with severe LV 415 dysfunction or poor oxygenation, however, different supplemental oxygen strategies may 416 have a differential impact on myocardial injury and other clinical outcomes. Therefore, 417 further studies are required of high-risk patients, who may be more suitable candidates for 418 419 TAVI. Lastly, there is lack of control subjects undergoing SAVR in evaluating oxygenation and perioprocedural myocardial injury in this study. As it is beyond the primary aim of the 420 present study, future studies can be conducted regarding periprocedural oxygen content and 421 myocardial injury in patients undergoing TAVI vs. SAVR. 422

423

# 424 **Conclusions**

In conclusion, the  $F_1O_2$  level did not have a significant effect on periprocedural myocardial injury following TAVI with general anesthesia. However, considering the marginal results, a benefit of low  $F_1O_2$  during TAVI could not be ruled out.

# 429 Acknowledgements

The authors gratefully acknowledge Sun-Young Jung, a statistician, who is collaborating with
our institution, for her assistance in the statistical analysis and invaluable advice and
comments.

433

# 434 **References**

- 1. Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, et al. New
- 436 WHO recommendations on intraoperative and postoperative measures for surgical site
- 437 infection prevention: an evidence-based global perspective. Lancet Infect Dis 2016; 16:

438 e288–e303. doi: 10.1016/S1473-3099(16)30402-9.

- 439 2. Fasquel C, Huet O, Ozier Y, Quesnel C, Garnier M. Effects of intraoperative high
- 440 versus low inspiratory oxygen fraction (FiO2) on patient's outcome: A systematic
- review of evidence from the last 20 years. Anaesth Crit Care Pain Med 2020; 39: 847–
- 442 858. doi: 10.1016/j.accpm.2020.07.019.
- 443 3. Holse C, Aasvang EK, Vester-Andersen M, Rasmussen LS, Wetterslev J, Christensen
- R, et al. Hyperoxia and Antioxidants for Myocardial Injury in Noncardiac Surgery: A 2
- 445 x 2 Factorial, Blinded, Randomized Clinical Trial. Anesthesiology 2022; 136: 408-419.
- 446 doi: 10.1097/ALN.00000000004117.
- 447 4. Damiani E, Donati A, Girardis M. Oxygen in the critically ill: friend or foe? Curr Opin
  448 Anaesthesiol 2018; 31: 129–135. doi: 10.1097/ACO.00000000000559.
- 5. Cabello JB, Burls A, Emparanza JI, Bayliss SE, Quinn T. Oxygen therapy for acute
- 450 myocardial infarction. Cochrane Database Syst Rev 2016; 12: CD007160. doi:
- 451 10.1002/14651858.CD007160.pub4.
- 452 6. Hafner C, Wu J, Tiboldi A, Hess M, Mitulovic G, Kaun C, et al. Hyperoxia Induces

- 453 Inflammation and Cytotoxicity in Human Adult Cardiac Myocytes. Shock 2017; 47:
- 454 436–444. doi: 10.1097/SHK.00000000000740.
- 455 7. Carrabba N, Valenti R, Migliorini A, Vergara R, Parodi G, Antoniucci D. Prognostic
- 456 value of myocardial injury following transcatheter aortic valve implantation. Am J
- 457 Cardiol 2013; 111: 1475–1481. doi: 10.1016/j.amjcard.2013.01.301.
- 8. Barbash IM, Dvir D, Ben-Dor I, Badr S, Okubagzi P, Torguson R, et al. Prevalence and
- 459 effect of myocardial injury after transcatheter aortic valve replacement. Am J Cardiol

460 2013; 111: 1337–1343. doi: 10.1016/j.amjcard.2012.12.059.

- 461 9. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using
- standardized serum creatinine values in the modification of diet in renal disease study
- 463 equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247–254.

doi: 10.7326/0003-4819-145-4-200608150-00004.

- Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin
  Pract 2012; 120: c179–184. doi: 10.1159/000339789.
- 11. Azarbal A, Malenka DJ, Huang YL, Ross CS, Solomon RJ, DeVries JT, et al. Recovery
- 468 of Kidney Dysfunction After Transcatheter Aortic Valve Implantation (from the
- 469 Northern New England Cardiovascular Disease Study Group). Am J Cardiol 2019; 123:

470 426–433. doi: 10.1016/j.amjcard.2018.10.042.

- 12. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, et
- al. Updated standardized endpoint definitions for transcatheter aortic valve
- 473 implantation: the Valve Academic Research Consortium-2 consensus document. Eur
- 474 Heart J 2012; 33: 2403–2418. doi: 10.1093/eurheartj/ehs255.
- 13. Dworakowski R, Wendler O, Bhan A, Smith L, Pearson P, Alcock E, et al. Successful
- 476 transcatheter aortic valve implantation (TAVI) is associated with transient left
- 477 ventricular dysfunction. Heart 2012; 98: 1641–1646. doi: 10.1136/heartjnl-2012-

478 302505.

- 479 14. Kim WK, Rolf A, Liebetrau C, Van Linden A, Blumenstein J, Kempfert J, et al.
- 480 Detection of myocardial injury by CMR after transcatheter aortic valve replacement. J
- 481 Am Coll Cardiol 2014; 64: 349–357. doi: 10.1016/j.jacc.2014.03.052.
- 482 15. Sarraf M, Burkhoff D, Brener MI. First-in-Man 4-Chamber Pressure-Volume Analysis
- 483 During Transcatheter Aortic Valve Replacement for Bicuspid Aortic Valve Disease.
- 484 JACC Case Rep 2021; 3: 77–81. doi: 10.1016/j.jaccas.2020.11.041.
- 16. Kim WK, Liebetrau C, van Linden A, Blumenstein J, Gaede L, Hamm CW, et al.
- 486 Myocardial injury associated with transcatheter aortic valve implantation (TAVI). Clin

487 Res Cardiol 2016; 105: 379–387. doi: 10.1007/s00392-015-0949-6.

- 488 17. Selle A, Figulla HR, Ferrari M, Rademacher W, Goebel B, Hamadanchi A, et al.
- Impact of rapid ventricular pacing during TAVI on microvascular tissue perfusion. Clin
  Res Cardiol 2014; 103: 902–911. doi: 10.1007/s00392-014-0728-9.
- 18. Acheampong A, Melot C, Benjelloun M, Cheval M, Reye F, Delporte C, et al. Effects
- 492 of hyperoxia and cardiovascular risk factors on myocardial ischaemia-reperfusion
- 493 injury: a randomized, sham-controlled parallel study. Exp Physiol 2021; 106: 1249–

494 1262. doi: 10.1113/EP089320.

495 19. Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on left ventricular

496 function and filling pressures in patients with and without congestive heart failure.

497 Chest 2001; 120: 467–473. doi: 10.1378/chest.120.2.467.

- 498 20. Kelly RF, Hursey TL, Parrillo JE, Schaer GL. Effect of 100% oxygen administration on
- infarct size and left ventricular function in a canine model of myocardial infarction and
- reperfusion. Am Heart J 1995; 130: 957–965. doi: 10.1016/0002-8703(95)90194-9.
- 501 21. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, et al. Air Versus
- 502 Oxygen in ST-Segment-Elevation Myocardial Infarction. Circulation 2015; 131: 2143–

503 2150. doi: 10.1161/CIRCULATIONAHA.114.014494.

- 504 22. Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, et al. Effect of
- 505 Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an
- 506 Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial. JAMA 2016; 316:
- 507 1583–1589. doi: 10.1001/jama.2016.11993.
- 508 23. Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. Oxygen
- 509 Therapy in Suspected Acute Myocardial Infarction. N Engl J Med 2017; 377: 1240–

510 1249. doi: 10.1056/NEJMoa1706222.

- 511 24. ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society
- 512 Clinical Trials Group, Mackle D, Bellomo R, Bailey M, Beasley R, Deane A, et al.
- 513 Conservative Oxygen Therapy during Mechanical Ventilation in the ICU. N Engl J

514 Med 2020; 382: 989–998. doi: 10.1056/NEJMoa1903297.


- Stewart RAH, Jones P, Dicker B, Jiang Y, Smith T, Swain A, et al. High flow oxygen
  and risk of mortality in patients with a suspected acute coronary syndrome: pragmatic,
- cluster randomised, crossover trial. BMJ 2021; 372: n355. doi: 10.1136/bmj.n355.
- 518 26. Buse GL, Matot I. Pro-Con Debate: Cardiac Troponin Measurement as Part of Routine
- 519 Follow-up of Myocardial Damage Following Noncardiac Surgery. Anesth Analg 2022;
- 520 134: 257–265. doi: 10.1213/ANE.00000000005714.
- 521 27. Michail M, Cameron JN, Nerlekar N, Ihdayhid AR, McCormick LM, Gooley R, et al.
- 522 Periprocedural Myocardial Injury Predicts Short- and Long-Term Mortality in Patients
- 523 Undergoing Transcatheter Aortic Valve Replacement. Circ Cardiovasc Interv 2018; 11:
- 524 e007106. doi: 10.1161/CIRCINTERVENTIONS.118.007106.
- 525 28. Lahoud R, Butzel DW, Parsee A, Huang YL, Solomon RJ, DeVries JT, et al. Acute
- 526 Kidney Recovery in Patients Who Underwent Transcatheter Versus Surgical Aortic
- 527 Valve Replacement (from the Northern New England Cardiovascular Disease Study

528		Group). Am J Cardiol 2020; 125: 788–794. doi: 10.1016/j.amjcard.2019.11.024.
529	29.	Peillex M, Marchandot B, Matsushita K, Prinz E, Hess S, Reydel A, et al. Acute kidney
530		injury and acute kidney recovery following Transcatheter Aortic Valve Replacement.
531		PLoS One 2021; 16: e0255806. doi: 10.1371/journal.pone.0255806.
532		
533	Su	pporting information
534	S1 F	ig. Changes in cardiac biomarkers in the first 72 h in patients including five
535	patio	ents who were excluded from the main analysis due to pre-procedural elevation of
536	card	iac biomarkers after randomization and received a fraction of inspired oxygen of
537	<b>0.3</b> o	or 0.8 during transcatheter aortic valve implantation. AUC, area under the curve; CK-

- 538 MB, creatine kinase-myocardial band; hs-cTnI, high sensitivity cardiac troponin I; TAVI,
- 539 transcatheter aortic valve implantation.
- 540 S1 CONSORT Checklist.
- 541

# 542 Financial disclosure statement

543 The authors received no specific funding for this work.



# Figure1






Figure2





# Figure3